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ABSTRACT: The constant and persistent synthesis and abuse of new psychoactive
substances have sparked the requirement for rapid, on-site, sensitive analytical
protocols for their sensing and quantiﬁcation. Mephedrone (4-MMC) is currently one
of the most popular legal highs among recreational drug abusers and imposes a serious
public health problem. In this paper, the electrochemical sensing of two metabolites of
4-MMC, namely, nor-mephedrone (4-methylcathinone, 4-MC) and dihydromephe-
drone (4-methylephedrine, 4-MMC-R), utilizing screen-printed graphite electrodes is
performed. The accessible linear ranges by cyclic voltammetry were found to
correspond to 40−300 μg mL−1 for 4-MC in both phosphate buﬀer solution (PBS,
pH 7.0) and spiked diluted human urine, whereas in the case of 4-MMC-R, the
linearity ranges are 15−300 μg mL−1 (PBS, pH 3.0) and 25−300 μg mL−1 (spiked
diluted human urine). To maximize the assay sensitivity, diﬀerential pulse
voltammetry (DPV) was performed toward the sensing of 4-MC, which exhibited a
linear response over the range 10−250 and 10−300 μg mL−1 in PBS pH 7.0 and spiked diluted human urine, respectively.
However, 4-MMC-R demonstrated slightly higher sensitivity over the range 5−300 μg mL−1 in both PBS pH 3.0 and spiked
diluted human urine. Using DPV, the limits of detection (3σ) were calculated and found to correspond to ca. 3.97 and 3.64 μg
mL−1 for 4-MC and 4-MMC-R (PBS, pH 7.0 and 3.0), respectively, and ca. 6.34 and 3.87 μg mL−1 for 4-MC and 4-MMC-R
(spiked diluted human urine), respectively. The potential interference of adulterants’ metabolites commonly found in NPS
street samples was also explored (at both pH 7.0 and 3.0). The electrochemical approach reported herein provides a novel
laboratory tool for the identiﬁcation and quantiﬁcation of synthetic cathinone metabolites and has potential for the basis of a
portable analytical sensor for their fast, cheap, reliable, and accessible determination in the ﬁeld.
■ INTRODUCTION
New psychoactive substances (NPS), typically referred to as
“legal highs” or “designer drugs”, are synthetic compounds that
mimic the eﬀects of common controlled substances but are not
controlled under the Misuse of Drugs Act (1971).1 Worldwide,
these NPS pose extensive problems for law enforcement
agencies as well as public health oﬃcials, as they have triggered
many serious public health implications typically ending with
fatal repercussions.2 In 2013, the European Monitoring Centre
for Drugs and Drug Addiction (EMCDDA) monitored more
than 350 NPS appearing across Europe.3 In 2015, the EU Early
Warning System (EU EWS) reported around 80 000 seizures as
a result of abuse of diﬀerent kinds of NPS, of which synthetic
cathinones (SC) contributed to 33% of the total NPS seizures.4
By the end of 2017, the number of NPS monitored by the
EMCDDA reached over 670 according to their 2018 annual
report.5 SC are structurally related to the natural stimulant
(±)-cathinone found in the leaves of the Khat plant (Catha
edulis, a wild plant grown in the Horn of Africa and in the
southwest Arabian Peninsula).6 SC possess amphetamine-like
pharmacological properties and provide a cheap alternative to
the phenethylamine class of psychoactive substances.6,7 One of
the most popular and extensively abused SC in the recreational
drug market is (±)-4-methyl-N-methylcathinone or (±)-meph-
edrone (4-MMC) (Scheme 1).
4-MMC was ﬁrst synthesized by Sanchez in 1929,8 however,
the compound was ignored until its abuse in the early 2000s and
used as a legal alternative to (±)-3,4-methylendioxymethampet-
amine (ecstasy) or cocaine.9 The ﬁrst reported seizure from the
abuse of 4-MMCwas in Finland in 2007.10 In 2010, 4-MMCwas
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detected and seized in 28 European and neighboring
countries,11 and it was the third commonly abused drug in the
U.K.9 In April 2010, the U.K. controlled 4-MMC and listed it
under class B substances in the Misuse of Drugs Act (1971).12
Similarly, the European Council, in December 2010, adopted a
decision on submitting 4-MMC to control measures across the
European Union.13 Later in 2012, the US classiﬁed 4-MMC as a
“Schedule I drug” under the Synthetic Drug Abuse Prevention
Act of 2012.14 Despite the legislative constraints imposed in
2010 and 2012, many 4-MMC related fatalities have been
reported afterward.15−17 Therefore, the need to develop a rapid,
cost-eﬀective, on-site detection strategy is crucial for law
enforcement oﬃcials. 4-MMC undergoes extensive metabolism
upon its administration, giving rise to several metabolites (phase
I and phase II metabolites).18 Many of these metabolites have
been described both in vitro19,20 and in vivo, in humans.18 The
postulated phase I metabolic pathways were as follows (Scheme
1): (i) N-demethylation of the primary amine to form nor-
mephedrone (4-methylcathinone, 4-MC), (ii) reduction of the
β-keto moiety to the respective alcohol named dihydromephe-
drone (4-methylephedrine, 4-MMC-R), (iii) oxidation of the
tolyl moiety to the corresponding alcohol, 4-hydroxytolylme-
phedrone, which undergoes further oxidation to the respective
carboxylic acid, termed as 4-carboxymephedrone.18,19,21
Although many reports adopted the pharmacokinetic study of
4-MMC, only one paper published the approximate concen-
trations of 4-MMC metabolites excreted in human urine as
follows: (i) unchanged 4-MMC% recovered in urine = 1.15% of
the ingested 4-MMC dose, (ii) 4-MC % = 10% of total 4-MMC
excreted in urine, (iii) 4-MMC-R % = 20% of total 4-MMC
excreted in urine, (iv) 4-carboxymephedrone % = major
metabolite in urine, exists as 10 times the amount of 4-MMC
excreted in urine.22 As described in (Table 1), typical
quantiﬁcation of 4-MMC metabolites is via liquid chromatog-
raphy mass spectrometry (LC/MS)23−26 and gas chromatog-
raphy mass spectrometry (GC/MS).27,28 Therefore, upon
consultation of the literature, it is apparent that all of the
current developed methods, for the quantiﬁcation of 4-MMC
metabolites, cannot be utilized as a low-cost, portable sensing
platform.
Forensic electrochemistry has been extensively reported as an
advantageous analytical tool that is adaptable to hand-held
devices, in light of its portability, sensitivity, and selectivity.29,30
Screen-printed graphite electrodes (SPEs) are useful analytical
platforms within forensic electrochemistry and have been
regularly applied for the electrochemical quantiﬁcation of a
range of target analytes,31,32 given that they enable the
translation of laboratory experiments into the “ﬁeld” due to
their portability, low cost, easy to use, and disposable nature that
render them the sensors of choice for on-site detection of drugs
of abuse by police oﬃcers and forensic analysts. Consequently,
the electrochemical sensing of 4-MMC metabolites (4-MC and
4-MMC-R) is reported for the ﬁrst time utilizing disposable
SPEs. The proposed protocol has been validated in both ideal
buﬀer solutions as well as in spiked diluted human urine by using
both cyclic voltammetry (CV) and diﬀerential pulse voltamme-
try (DPV). Additionally, the metabolites of the 4-MMC
adulterants (that are typically found in street samples) are
electrochemically characterized for their potential interference
in the simultaneous sensing of 4-MC and 4-MMC-R. To the best
of our knowledge, no established on-site portable methodology
has been developed for the quantiﬁcation of 4-MMC
metabolites: 4-MC and 4-MMC-R.
■ RESULTS AND DISCUSSION
The electrochemical sensing of mephedrone metabolites, 4-MC
and 4-MMC-R, is reported for the ﬁrst time utilizing disposable
graphite screen-printed electrodes (SPEs). First, the eﬀects of
the buﬀer pH and applied voltammetric scan rate were explored
and analyzed to ﬁnd the optimal analytical signal/voltammetric
output; these data are presented in detail within the Supporting
Information (SI). Brieﬂy, the optimum pH values for the
electrochemical reduction of 4-MC and electrochemical
oxidation of 4-MMC-R within a phosphate buﬀer solution
(PBS) were found to correspond to pH 7.0 and 3.0, respectively
(Figures S1 and S2). Additionally, analysis of peak potential vs
pH indicates gradient values close to that expected for a one-
proton and two-electron process (33 mV per pH unit at 25 °C)
for both metabolites. The eﬀect of voltammetric scan rate (v)
upon the electrochemical response of both metabolites was also
studied (see SI), indicating that the electrochemical detection of
both metabolites undergoes diﬀusion controlled processes
(Figures S3 and S4). Next, cyclic voltammetric measurements
were performed using graphite screen-printed electrodes (SPEs)
for the analyses of 4-MC and 4-MMC-R in 0.1 M PBS at pH 7.0
and 3.0, respectively. It is important to note that in all cases, a
new SPE was used for each analytical scan/detection showing
the real beneﬁt of SPEs.
Figure 1 depicts the cyclic voltammetric signatures of both 4-
MC (Figure 1A) and 4-MMC-R (Figure 1B) where the
electrochemical reduction and oxidation peaks are observed at
peak potentials (Ep,red/V) ≈ −1.56 V and (Ep,ox/V) ≈ +0.91 V,
for 4-MC and 4-MMC-R, respectively. The electroanalytical
quantiﬁcation of the metabolites is next considered and
Scheme 1. Proposed Pathways for Phase I Metabolism of
Mephedrone (4-MMC)19
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validated according to the International Conference on
Harmonization guidelines. Cyclic voltammetric and diﬀerential
pulse voltammetric measurements were next performed in 0.1M
PBS, using pH 7.0 and 3.0 for the quantitation of 4-MC and 4-
MMC-R (Figures 2 and 3). A series of increasing concentrations
were analyzed for each metabolite using cyclic voltammetry and
diﬀerential pulse voltammetry, and calibration plots were
constructed for 4-MC and 4-MMC-R. Upon the application of
cyclic voltammetry, it was deduced that 4-MC exhibits a linear
plot over the concentration range 40−300 μg mL−1, the
regression equation was: Ip (μA) =−0.9336 μA− 0.0344 μA/μg
mL−1, R2 = 0.999 (inset Figure 2A). The limit of detection
(LOD) was calculated using the formula 3Sa/b (where “Sa” is
the standard deviation of the intercept of the calibration curve
and “b” is the slope of the calibration curve), and it corresponds
to 7.11 μg mL−1. Likewise, upon quantiﬁcation of 4-MMC-R by
cyclic voltammetry, a calibration plot was generated in the linear
range 15−300 μg mL−1; with regression equation: Ip (μA) =
−0.3443 μA + 0.0314 μA/μgmL−1, R2= 0.999 (inset Figure 2B).
The LOD was calculated using the same formula previously
described, and it corresponds to 4.39 μg mL−1. However, the
sensitivity and the detection limits were slightly enhanced by the
application of diﬀerential pulse voltammetry, where 4-MC was
found to be linear in the range 10−250 μg mL−1; with regression
equation: Ip (μA) = −0.6101 μA − 0.0603 μA/μg mL−1, R2 =
0.999 (inset Figure 3B), and the calculated LOD is equivalent to
3.97 μg mL−1. In case of 4-MMC-R, it exhibits a linear response
over the concentration range 5−300 μg mL−1; with regression
equation: Ip (μA) = −0.0214 μA + 0.031 μA/μg mL−1, R2 =
0.999 (inset Figure 3B), and the calculated LOD is equivalent to
3.64 μg mL−1.
Precision, robustness, and selectivity studies are included in
the Supporting Information, exhibiting a good reproducibility
when using a new SPE for each sample/test. Selectivity studies
were performed using the metabolites of common adulterants
present in street samples, benzocaine, caﬀeine and paracetamol
ﬁnding that none of them interferes in the electrochemical
reduction of 4-MC, and only the paracetamol metabolite β-D-
glucuronide demonstrated an oxidation peak in the positive
potential window that could potentially interfere with the
electrochemical oxidation of 4-MMC-R.
Analytical Application (Application of the Method to
Spiked Diluted Human Urine). To evaluate the analytical
Figure 1. Cyclic voltammetric proﬁles obtained using graphite screen-printed electrodes (SPEs) in: (A) PBS buﬀer (0.1 M, pH 7.0) in the presence
(solid line) and in absence (dotted line) of 200 μg mL−1 of 4-MC, (B) PBS buﬀer (0.1 M, pH 3.0) in the presence (solid line) and in absence (dotted
line) of 100 μg mL−1 of 4-MMC-R. Scan rate: 50 mV s−1 (vs Ag/AgCl). Note in all cases, each plot/voltammogram is a new SPE.
Figure 2. (A) Cyclic voltammograms using SPEs in 0.1 M PBS buﬀer
(pH 7.0) as a result of increasing concentrations of 4-MC (40−300 μg
mL−1). Inset: corresponding analytical calibration plot of Ip vs 4-MC
concentration; scan rate: 50 mV s−1 (vs Ag/AgCl). (B) Cyclic
voltammograms using SPEs in 0.1 M PBS buﬀer (pH 3.0) as a result of
increasing concentrations of 4-MMC-R (15−300 μg mL−1). Inset:
corresponding analytical calibration plot of Ip vs 4-MMC-R
concentration; scan rate: 50 mV s−1 (vs Ag/AgCl).
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applicability of the developed methods, calibration curves were
constructed for both 4-MC and 4-MMC-R, in spiked diluted
human urine samples using both cyclic voltammetry and
diﬀerential pulse voltammetry. Using cyclic voltammetry, 4-
MC and 4-MMC-R exhibit a linear behavior over the
concentration range 40−300 and 25−300 μgmL−1, respectively.
The linear regression equations can be represented as: Ip (μA) =
−0.8136 μA− 0.0385 μA/μg mL−1; R2 = 0.998 (Figure 4A) and
Ip (μA) =−0.0204 μA+ 0.0083 μA/μgmL−1;R2 = 0.999 (Figure
4B), for 4-MC and 4-MMC-R, respectively. The LOD
(calculated as above) were found to correspond to 8.86 and
6.22 μg mL−1 for 4-MC and 4-MMC-R, respectively, which are
in agreement with the ﬁgures computed when validating the two
metabolites in buﬀer solutions. The detection limits were
slightly enhanced upon the application of DPV, where 4-MC
and 4-MMC-R were found to be linear over the concentration
range 10−300 and 5−300 μg mL−1, respectively. The
corresponding regression equations and the calculated LOD
are: Ip (μA) = −0.6236 μA − 0.0384 μA/μg mL−1; R2 = 0.998,
LOD = 6.34 μg mL−1 for 4-MC (Figure 5A) and Ip (μA) =
0.1582 μA + 0.0359 μA/μg mL−1; R2 = 0.999, LOD = 3.87 μg
mL−1 for 4-MMC-R (Figure 5B), for 4-MMC-R. The
aforementioned validation data obtained from spiked diluted
human urine demonstrated that the developed electrochemical
sensing methodologies can held a great promise for the reliable
and sensitive quantitations of 4-MC and 4-MMC-R in the
clinical analysis.
Figure 3. (A) Plot of peak current (Ip) as a function of 4-MC in concentration range 10−250 μg mL−1 in 0.1 M PBS (pH 7.0) using diﬀerential pulse
voltammetry. (B) Plot of peak current (Ip) as a function of 4-MMC-R in concentration range 5−300 μg mL−1 in 0.1 M PBS (pH 3.0) using diﬀerential
pulse voltammetry. Modulation amplitude: 0.1 V; modulation time: 0.02 s; interval time: 0.1 s; step: 0.005 V; scan rate: 50 mV s−1 (vs Ag/AgCl).
Figure 4. (A) Cyclic voltammograms using SPEs in human urine spiked with diﬀerent concentrations of 4-MC (40−300 μg mL−1). Inset:
corresponding analytical calibration plot of Ip vs 4-MC concentration; scan rate: 50 mV s
−1 (vs Ag/AgCl). (B) Cyclic voltammograms using SPEs in
human urine spiked with diﬀerent concentrations of 4-MMC-R (25−300 μg mL−1). Inset: corresponding analytical calibration plot of Ip vs 4-MMC-R
concentration; scan rate: 50 mV s−1 (vs Ag/AgCl).
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■ CONCLUSIONS
For the ﬁrst time, the electrochemical detection of mephedrone
metabolites, namely nor-mephedrone (4-MC) and 4-methyl-
ephedrine (4-MMC-R), was found to be viable via the use of
graphite SPEs in both model buﬀer solutions and diluted human
urine using CV and DPV. The applied methodologies are
simple, reliable, rapid, and sensitive; where the diﬀerential pulse
voltammetric measurements oﬀered a limit of detection (LOD,
3σ) of 3.97 and 3.64 μg mL−1 for 4-MC and 4-MMC-R,
respectively, in the buﬀer solution and 6.34 and 3.87 μgmL−1 for
4-MC and 4-MMC-R, respectively, in spiked diluted human
urine samples. To date, current employed methods for the
detection and quantiﬁcation of these substances rely on the use
of mass detectors that are expensive and cannot be tailored for
on-site screening. However, the reported electrochemical
protocols beneﬁt from the portable and disposable nature of
SPEs. The metabolites of adulterants, likely to be found in “legal
high” street samples, paracetamol β-D-glucuronide, 1-methyluric
acid, and 4-acetamidobenzoic acid, have also been explored at
the optimum pH buﬀer using cyclic voltammetry. In PBS buﬀer
pH 3.0, there is no electrochemical selectivity over the
electrochemical detection of 4-MMC-R in the presence of
paracetamol β-D-glucuronide, however, this interference was not
visible upon 4-MC determination. Future work is directed to
overcome this limiting issue of overlapping voltammetric waves
using high-performance liquid chromatography with an electro-
chemical detector.
Experimental Section.All chemicals were of pure analytical
grade (obtained from Sigma-Aldrich Co. Ltd., Gillingham, U.K.)
and were used as received without any further puriﬁcation. All
solutions were prepared with Milli-Q deionized water with a
resistivity of no less than 18.2 Ω cm−1 (Millipore system). All
solutions (unless stated otherwise) were vigorously degassed for
10 min with high purity nitrogen to remove oxygen prior to
analysis. Samples of mephedrone (4-MMC) and its metabolites
(nor-mephedrone, 4-MC and 4-methylephedrine, 4-MMC-R)
were prepared, under U.K. Home Oﬃce Drug Licence (No.
337201), as their corresponding hydrochloride salts at Man-
chester Metropolitan University. The synthesis of the racemic
target compounds was achieved using the previously reported
method by Mayer et al.33 in 15% (4-MMC and 4-MMC-R) −
37% (4-MC) overall yield. The hydrochloride salts were
obtained as stable, oﬀ-white powders and determined to be
soluble (10 mg mL−1) in deionized water, methanol, and
dimethylsulfoxide. To ensure the authenticity of the materials
utilized in this study, the synthesized samples were fully
structurally characterized by 1H NMR,13C NMR, GC−MS,
and ATR−FTIR, and the purity of all samples conﬁrmed by
elemental analysis (>99.6% in all cases).33
Voltammetric measurements were conducted using a
“μAutolab type III” (Metrohm Autolab, The Netherlands)
potentiostat/galvanostat interfaced to a PC loaded with NOVA
2.1 software. All measurements were carried out using graphite
screen-printed macroelectrodes (SPEs) (with the dimensions of
41 mm long × 7 mm wide) that comprise of a three-electrode
conﬁguration with a 3.1 mm diameter graphite working
electrode, a graphite counter and a Ag/AgCl reference electrode.
The SPEs were fabricated in house at Manchester Metropolitan
University (MMU) have been previously characterized34,35 and
are incorporated into an “edge connector” to accommodate the
SPE while electrically connected to the potentiostat as
previously reported.36,37 Voltammetric measurements were
carried out upon applying 30 μL of solution by micropipette
onto the electrode surface, such that the three partitions are
covered with solution. Note that a new/separate SPE was used
for each voltammogram acquired, and all measurements were
conducted at ambient temperature.
Preparation of the metabolites standard stock solutions,
calibration curve working standard solutions, and selectivity
standards are described in details in the Supporting Information
(SI).
Application of the Method to Biological Samples
(Spiked Diluted Human Urine Samples). For the
application of the biological sample, fresh urine samples were
collected from healthy volunteers on the same day of the
experiments. All experiments were performed in accordance
with the applicable laws and formal rules, and the oﬃcial ethics
committees have approved these experiments. Urine sample
(10.0 mL) was added separately to two 200.0 mL glass
volumetric ﬂasks, one ﬂask was made to the mark with 0.1 M
PBS buﬀer pH 7.0 (Solution 1) and the other was made to
volume with 0.1 M PBS buﬀer pH 3.0 (Solution 2). Solution 1
and Solution 2 were used to prepare 1 mg mL−1 of 4-MC and 4-
MMC-R standard stock solutions, respectively. Thereafter, two
separate sets of 5.0 mL volumetric ﬂasks were spiked with
diﬀerent volumes of 4-MC and 4-MMC-R standard stock
solutions, and the ﬂask set containing 4-MC was completed to
Figure 5. (A) Plot of peak current (Ip) as a function of 4-MC in concentration range 10−300 μg mL−1 in human urine using diﬀerential pulse
voltammetry. (B) Plot of peak current (Ip) as a function of 4-MMC-R in concentration range 5−300 μg mL−1 in human urine using diﬀerential pulse
voltammetry. Modulation amplitude: 0.1 V; modulation time: 0.02 s; interval time: 0.1 s; step: 0.005 V; scan rate: 50 mV s−1 (vs Ag/AgCl).
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volume with Solution 1, whereas the other ﬂask set containing 4-
MMC-R was completed to the mark with Solution 2. All of the
solutions were degassed for 10 min with highly pure nitrogen,
with the voltammetric measurements (CV and DPV) being
carried out directly without any further pretreatment.
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